Literature DB >> 30905655

Therapeutic potential of pharmacological TGF-β signaling pathway inhibitors in the pathogenesis of breast cancer.

Mahdieh Khoshakhlagh1, Atena Soleimani2, Maryam Moradi Binabaj1, Amir Avan3, Gordon A Ferns4, Majid Khazaei5, Seyed Mahdi Hassanian6.   

Abstract

The TGF-β signaling pathway plays an important role in cancer cell proliferation, growth, inflammation, angiogenesis, and metastasis. The role of TGF-β signaling in the pathogenesis of breast cancer is complex. TGF-β acts as a tumor suppressor in the early stages of disease, and as a tumor promoter in its later stages. Over-activation of the TGF-β signaling pathway and over-expression of the TGF-β receptors are frequently found in breast tumors. Suppression of TGF-β pathway using biological or pharmacological inhibitors is a potentially novel therapeutic approach for breast cancer treatment. This review summarizes the regulatory role of TGF-β signaling in the pathogenesis of breast cancer for a better understanding and hence a better management of this disease.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Breast cancer; Pharmacological inhibitors; TGF-β receptors; TGF-β signaling

Mesh:

Substances:

Year:  2019        PMID: 30905655     DOI: 10.1016/j.bcp.2019.03.031

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

1.  Possible involvement of TGF‑β‑SMAD‑mediated epithelial‑mesenchymal transition in pro‑metastatic property of PAX6.

Authors:  Meng Jin; Daili Gao; Rongchun Wang; Attila Sik; Kechun Liu
Journal:  Oncol Rep       Date:  2020-06-11       Impact factor: 3.906

2.  Inhibition of transforming growth factor-beta by Tranilast reduces tumor growth and ameliorates fibrosis in colorectal cancer.

Authors:  Milad Hashemzehi; Negar Yavari; Farzad Rahmani; Fereshteh Asgharzadeh; Atena Soleimani; Neda Shakour; Amir Avan; Farzin Hadizadeh; Maryam Fakhraie; Reyhaneh Moradi Marjaneh; Gordon A Ferns; Parham Reisi; Mikhail Ryzhikov; Majid Khazaei; Seyed Mahdi Hassanian
Journal:  EXCLI J       Date:  2021-03-09       Impact factor: 4.068

3.  A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome?

Authors:  Maryam Joudi; Maryam Moradi Binabaj; Pejman Porouhan; Babak PeyroShabany; Mohsen Tabasi; Danial Fazilat-Panah; Mahtab Khajeh; Arezoo Mehrabian; Mansoureh Dehghani; James S Welsh; Batol Keykhosravi; Azam Akbari Yazdi; Mona Ariamanesh; Ahmad Ghasemi; Gordon Ferns; Seyed Alireza Javadinia
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-01       Impact factor: 5.555

Review 4.  Transforming growth factor-β in tumour development.

Authors:  Charles B Trelford; Lina Dagnino; Gianni M Di Guglielmo
Journal:  Front Mol Biosci       Date:  2022-10-04

Review 5.  The genomic architecture of metastasis in breast cancer: focus on mechanistic aspects, signalling pathways and therapeutic strategies.

Authors:  Yogita Chhichholiya; Prabhat Suman; Sandeep Singh; Anjana Munshi
Journal:  Med Oncol       Date:  2021-07-16       Impact factor: 3.064

6.  Overexpression of GUCY1A2 Correlates With Poor Prognosis in Gastric Cancer Patients.

Authors:  Xin Li; Xiaowei Chen; Xueju Hu; Yan Shen; Rui Xu; Leilei Wu; Xiaobing Shen
Journal:  Front Oncol       Date:  2021-05-25       Impact factor: 6.244

7.  Normal cells repel WWOX-negative or -dysfunctional cancer cells via WWOX cell surface epitope 286-299.

Authors:  Yu-An Chen; Yong-Da Sie; Tsung-Yun Liu; Hsiang-Ling Kuo; Pei-Yi Chou; Yu-Jie Chen; Kuan-Ting Lee; Pin-Jun Chen; Shur-Tzu Chen; Nan-Shan Chang
Journal:  Commun Biol       Date:  2021-06-17

8.  Identification of three miRNAs signature as a prognostic biomarker in breast cancer using bioinformatics analysis.

Authors:  Meijie Sang; Aiying Li; Xu Wang; Can Chen; Kun Liu; Lin Bai; Ming Wu; Fei Liu; Meixiang Sang
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.